Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

IDEAYA Biosciences (IDYA) EBT (2020 - 2025)

Historic EBT for IDEAYA Biosciences (IDYA) over the last 6 years, with Q3 2025 value amounting to $108.5 million.

  • IDEAYA Biosciences' EBT rose 26212.76% to $108.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$167.5 million, marking a year-over-year increase of 2547.14%. This contributed to the annual value of -$327.0 million for FY2024, which is 14323.25% down from last year.
  • Latest data reveals that IDEAYA Biosciences reported EBT of $108.5 million as of Q3 2025, which was up 26212.76% from -$144.1 million recorded in Q4 2024.
  • Over the past 5 years, IDEAYA Biosciences' EBT peaked at $108.5 million during Q3 2025, and registered a low of -$144.1 million during Q4 2024.
  • Moreover, its 5-year median value for EBT was -$26.3 million (2023), whereas its average is -$27.4 million.
  • Its EBT has fluctuated over the past 5 years, first tumbled by 517969.7% in 2023, then surged by 26212.76% in 2025.
  • Quarter analysis of 5 years shows IDEAYA Biosciences' EBT stood at -$18.4 million in 2021, then crashed by 43.95% to -$26.4 million in 2022, then plummeted by 58.52% to -$41.9 million in 2023, then plummeted by 243.87% to -$144.1 million in 2024, then surged by 175.24% to $108.5 million in 2025.
  • Its EBT was $108.5 million in Q3 2025, compared to -$144.1 million in Q4 2024 and -$66.9 million in Q3 2024.